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ABSTRACT
Background Osteoarthritis is the most common form
of arthritis and a major socioeconomic burden. Our
study is the first to explore the association between
serum microRNA levels and the development of severe
osteoarthritis of the knee and hip joint in the general
population.
Methods We followed 816 Caucasian individuals from
1995 to 2010 and assessed joint arthroplasty as a
definitive outcome of severe osteoarthritis of the knee and
hip. After a microarray screen, we validated 12 microRNAs
by real-time PCR in the entire cohort at baseline.
Results In Cox regression analysis, three microRNAs were
associated with severe knee and hip osteoarthritis. let-7e
was a negative predictor for total joint arthroplasty with an
adjusted HR of 0.75 (95% CI 0.58 to 0.96; p=0.021)
when normalised to U6, and 0.76 (95% CI 0.6 to 0.97;
p=0.026) after normalisation to the Ct average. miRNA-
454 was inversely correlated with severe knee or hip
osteoarthritis with an adjusted HR of 0.77 (95% CI 0.61 to
0.97; p=0.028) when normalised to U6. This correlation
was lost when data were normalised to Ct average
(p=0.118). Finally, miRNA-885-5p showed a trend
towards a positive relationship with arthroplasty when
normalised to U6 (HR 1.24; 95% CI 0.95 to 1.62;
p=0.107) or to Ct average (HR 1.30; 95% CI 0.99 to
1.70; p=0.056).
Conclusions Our study is the first to identify differentially
expressed circulating microRNAs in osteoarthritis patients
necessitating arthroplasty in a large, population-based
cohort. Among these microRNAs, let-7e emerged as
potential predictor for severe knee or hip osteoarthritis.
INTRODUCTION
Osteoarthritis (OA) is the most common form of
arthritis and a leading cause of disability.1 In the
general population, the prevalence of knee and hip
OA ranges from 20 to 30%,1 and OA affecting
these two joints represents the major cause of lower
extremity disability among older adults.2 In add-
ition to the personal burden of the disease, Western
societies invest up to 2% of their gross national
product into the costs of OA resulting from loss of
work productivity and increased medical costs.3
According to recent reports from the Organisation
for Economic Co-operation and Development
(OECD), the number of joint replacement surgeries
as ultimate therapies for patients with knee and hip
OA has almost doubled during the past decade
(http://www.oecd-ilibrary.org).
OA is a progressive disease with a long silent
period, which shows signs of cartilage degradation,
mild-to-moderate synovial inflammation and
altered bone structure, resulting in severe destruc-
tion and impaired function of the affected joints.4
Clinical symptoms and radiographic changes gener-
ally guide the diagnosis, with plain radiography
remaining the gold standard. Radiography,
however, is limited by poor sensitivity that hampers
early detection of the disease and close follow-up.
By contrast, sensitive and specific blood biomarkers
to detect the initial stages of OA or even allow pre-
dicting the future development of the disease are
not available in clinical routine.5 Many experimen-
tal biomarkers of cartilage metabolism lack sensitiv-
ity for early disease stages, specificity for OA and/
or robust validation in large clinical studies.
MicroRNAs (miRNAs) are small non-coding
RNAs that regulate a broad spectrum of physio-
logical cell processes during development and
tissue homeostasis. Nascent miRNA transcripts are
processed by the enzymes Drosha and Dicer to
become mature miRNAs consisting of 21–25
nucleotides. Mature miRNAs associate with the
RNA-induced silencing complex (RISC) to repress
mRNA translation.6 7 Aberrant miRNA expression
or dysregulation of miRNA processing has been
linked to many pathologies, including cancer, car-
diovascular or rheumatic disease.7–9 Since miRNA
are protected from RNAse activity in the peripheral
blood, miRNAs may serve as excellent biomarkers
for physiological and pathological processes.10 11
Although dysregulated miRNA expression has
been well documented in the osteoarthritic cartil-
age,9 12–17 evidence on altered circulating miRNA
levels in OA patients is very limited.18 19 Hence, our
project is the first to investigate the differential
expression of circulating miRNAs in subjects with
and without incident OA in a large prospective
population-based cohort. Applying knee and hip
joint replacement surgeries as definitive outcomes of
severe OA, let-7e appeared to be the most promising
predictor of severe OA with lower levels showing a
dose-dependent association with increased frequen-
cies of joint replacement surgeries.
MATERIALS AND METHODS
Study subjects and sample collection
The Bruneck study is a prospective population-
based survey that has been successfully used to
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profile circulating miRNA levels in diabetes and cardiovascular
disease.20–28 The current study analysed the observation period
from 1995 to 2010 with the study visit in 1995 serving as base-
line (see also online supplement 1). The protocols of the
Bruneck study were approved by the appropriate ethics commit-
tees, and all study subjects gave their written informed consent.
Longitudinal assessment of arthroplasty between 1995 and
2010
Localisation, date and circumstances of total hip and knee
arthroplasty occurring between 1995 and 2010 were carefully
recorded using three sources of information: subject self-report,
medical records of the Bruneck Hospital and general practi-
tioners, and a standardised evaluation of all radiographs ever
taken on study subjects. Radiography was not routinely per-
formed on all study participants to limit radiation exposure, but
was initiated in those with symptoms suggestive of OA.
Arthroplasty following bone fractures (documented by radio-
graphs) was not considered in the current analysis. Subjects
receiving arthroplasty met the criteria for the diagnosis of OA
and showed OA of the hip or knee joint in at least two sequen-
tial radiographs (Kellgren-Lawrence score of 3 and 4) prior to
surgery.29 30 Independent readers (RL, CP, and AK) unaware of
the miRNA data assessed the radiographs. All arthroplasties
were performed by a single team of experienced orthopaedic
surgeons.
Clinical history, physical examination and routine laboratory
studies
Clinical history, physical examination and routine laboratory
studies were recorded as detailed in the online supplement 1.
Sampling strategy and miRNA analysis
For the microarray screening, pooled serum from individuals
with two or more knee/hip replacement surgeries due to OA
and pooled serum from control individuals were investigated. In
detail, two serum pools from 6 and 7 OA individuals and two
serum pools from 6 and 7 control individuals from the 1995
baseline visit were used. Control individuals were identical in
age (± 1 year), sex, menopausal status and body mass index (±
2 kg/m2), but had not received arthroplasty prior to or during
the study (figure 1). RNA extraction was performed using the
miRNeasy kit (Qiagen). miRNAs were reverse-transcribed using
the Megaplex Primer Pools (Human Pools AV.2.1), and expres-
sion was screened using a Human Taqman miRNA array (CardA
V.2.1, Applied Biosystems, Darmstadt, Germany) covering 377
unique miRNAs. The miRNAs U6 and miRNA-45 were used as
normalisation standards in the Taqman miRNA array.
Comparison of these 377 miRNAs between the pools of
patients with severe OA and the control pools revealed 12
miRNAs with differential expression. These 12 miRNAs were
measured by quantitative (q)-PCR (TaqMan miRNA assays,
Applied Biosystems) in the entire Bruneck Study cohort
(n=816) (figure 1). For the lack of generally accepted standards,
all qPCR data were standardised to Ct average (ie, the Ct
average of all miRNA measurements for each sample) or U6 (ie,
a small non-coding RNA, which fulfilled the following criteria:
detectable in all samples, low dispersion of expression levels and
null association with OA status). Detailed description of the
methodology and raw data of the qPCR measurements are pro-
vided in the online supplements 1 and 2.
Statistical analysis
Data were analysed using SPSS V.18.0 and STATA V.10.1 soft-
ware packages. Continuous variables were presented as means±
SD or median (IQR), and dichotomous variables as numbers
and percentages. We used general linear models or logistic
regression models adjusted for age, sex and body mass index
(BMI) to analyse differences in participant characteristics
between those who had arthroplasty during follow-up and those
who had not (table 1). Loge-transformed miRNAs were used for
all computations to reduce the effect of extreme observations.
Fold changes of individual miRNAs were calculated by dividing
loge-transformed miRNA levels in subjects with severe OA
requiring joint replacement and all other. For computation of
intervention rates, person-years of follow-up for each partici-
pant were accrued from the 1995 baseline until arthroplasty, age
90, death or 1 October 2010, whichever came first. Cox pro-
portional hazard models were fitted to assess the association
between miRNAs and arthroplasty due to severe OA during
follow-up 1995–2010. The proportional hazard assumption was
confirmed for miRNAs by testing their interaction with a func-
tion of survival time (Cox model with time-dependent covari-
ates). When the exact date of arthroplasty was not available, we
used the date of the first X-ray showing the implant as a surro-
gate. This may be viewed as an adequate approximation in most
individuals and, if at all, errors on the conservative side. The
base model was unadjusted, while multivariable models were
adjusted for established predictors of severe OA (age, sex, BMI).
Differential effects of miRNAs on the probability of arthroplasty
in subgroups according to age and sex were tested by inclusion
of appropriate interaction terms. Sensitivity analyses excluded
subjects with joint arthroplasty prior to 1995. All reported p
values were two-sided.
miRNA relevance network inference and analysis
Network inference algorithm was applied to evaluate global
expression properties of miRNAs in OA as described previ-
ously,24 26 and the profiles were interrogated using the context
likelihood of relatedness (CLR) between all possible miRNA
pairs. A 10% false discovery rate (FDR) threshold was applied
to the CLR networks, where the FDR was calculated using the
q-value method.31
RESULTS
Characteristics of the Bruneck cohort
The Bruneck population is highly representative of the general
community and shows characteristics similar to those of other
Western countries (table 1). The mean age was 62.9±11.1 years,
50.0% of the individuals were male and all subjects were of
Caucasian origin. During the 15-year follow-up, 67 of a total of
the 816 individuals in the Bruneck cohort had one or more total
joint replacement surgeries for severe knee or hip OA correspond-
ing to an intervention rate of 6.9 per 1000 person-years. A total of
28 individuals received arthroplasty because of knee OA (2.8 per
1000 patient-years) and 41 for hip OA (4.1 per 1000 patient-
years). Accordingly, two subjects received both hip and knee joints
between 1995 and 2010. Overall 18 individuals underwent two or
more arthroplasties due to severe OA during their lifetime.
Weight and BMI were significantly increased in subjects receiving
arthroplasty for knee or hip OA (p=0.001 and p=0.002, table 1).
Individuals with arthroplasty showed increased circumferences of
the waists and hips (p=0.004 and p=0.001, table 1), but the
waist-to-hip ratio did not differ compared with control subjects.
This suggested that overweight rather than visceral adiposity is
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related to severe OA of the hip or knee. Moreover, there was a
trend towards an increased age among individuals with arthroplasty
(p=0.053). By contrast, lifestyle variables and laboratory para-
meters did not differ between individuals with or without knee or
hip arthroplasty (table 1).
Circulating miRNA levels in the Bruneck study
We were particularly interested in the predictive value of circu-
lating miRNAs in the general population and therefore used
serum samples from the 1995 baseline visit. In the initial screen-
ing, differential expression of miRNAs was assessed in pooled
samples from 13 individuals with OA-related arthroplasty and
13 controls without arthroplasty matched for age, sex and BMI.
Screening 377 unique miRNAs, we found 12 differentially
expressed miRNA that were reliably detectable in circulation
(miRNA-122, miRNA-25, miRNA 28-3p, miRNA-93,
miRNA-140, miRNA-191, miRNA-342-3p, miRNA-146b,
miRNA-454, miRNA-885-5p, let- 7b, let-7e). These miRNAs
Figure 1 Study design. This study focused on the 1995–2010 follow-up period of the Bruneck cohort (1995, n=816). In this period, 67 individuals
received one or more total joint replacement surgeries for severe knee or hip osteoarthritis (OA), while 749 did not. Pooled samples from 13
individuals with total joint arthroplasty versus 13 control individuals matched for sex, menopausal status, age and body mass index were screened
for differential expression of miRNAs by TaqMan miRNA Array CardA for 377 unique miRNAs (screening phase: white area). The screening approach
revealed 12 differentially expressed miRNAs, which were then measured by qPCR in the entire Bruneck cohort. Analyses based on these 12 miRNAs
identified let-7e, miRNA-454 and miRNA-885-5p as potential predictors for severe OA of the knee and hip joints requiring arthroplasty in the
general community (validation phase: grey area).
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were then measured in the entire Bruneck cohort. For the lack
of generally accepted standards for miRNA analysis, we normal-
ised the miRNA expression levels to two different standards: (i)
U6, a small non-coding RNA, which fulfilled the following cri-
teria: detectable in all samples, low dispersion of expression
levels and no association with OA status. (ii) Ct average of all
tested miRNAs.
Unadjusted Cox regression analysis revealed that let-7e was
inversely related to arthroplasty irrespective of the method of stand-
ardisation (normalised to either U6 or CT average) (table 2). After
adjustment for sex, age and BMI, findings remained stable with an
adjusted HR of 0.75 (0.58 to 0.95; p=0.019) when normalised to
U6, and 0.76 (0.60 to 0.97; p=0.021) after normalisation to the Ct
average (table 2). Findings did not change appreciably when exclud-
ing subjects with arthroplasty before 1995 (HR 0.75 (0.58 to 0.96),
p=0.021 and 0.76 (0.60 to 0.97), p=0.026 for U6 and Ct average
normalised let-7e). There was no differential association between
let-7e and arthroplasty in sexes and age strata. Further analysis
demonstrated that the inverse association of let-7e was dose depend-
ent. The lower the let-7e baseline levels were, the higher was the
risk that individuals underwent more than one arthroplasty due to
severe hip or knee OA (figure 2). Finally, our findings were similar
when we analysed the relationship of let-7e with severe OA of
either the hip or the knee (online supplement 1).
Besides let-7e, two other miRNAs appeared to be differen-
tially expressed in the Bruneck cohort after adjusting for age,
sex and BMI. When normalised to U6, miRNA-454 was
inversely correlated with the development of OA requiring joint
replacement with an adjusted HR of 0.77 (0.61 to 0.97;
p=0.028; table 2). Significance, however, was lost when data
were normalised to the Ct average. A non-significant trend
towards an inverse relationship between miRNA-454 and
arthroplasty was observed (p=0.118). Similarly, miRNA-885-5p
showed a non-significant trend to a positive correlation with
arthroplasty after adjustment for age, sex and BMI when nor-
malised to U6 (HR 1.24; 0.95 to 1.62; p=0.107) or the Ct
average (HR 1.30; 0.99 to 1.70; p=0.056; table 2).
Further support to the putative value of miRNA signatures as
biomarkers was provided by the inference of miRNA relevance
network. A differential network structure was evident between
the 12 miRNAs in controls and patients with OA (FDR=10%).
The disease state was characterised by substantial edge rewiring:
the positions of let-7e as well as miRNA-454 and
miRNA-885-5p, the two miRNAs that were close to conven-
tional levels of significance after adjustment for Ct average, dif-
fered substantially between individuals receiving joint
arthroplasty and healthy controls, indicating a unique miRNA
signature for severe OA (figure 3). In a forward stepwise selec-
tion model with a fixed entry of age, sex and BMI and allowing
for all miRNAs listed in table 2, let-7e and either miRNA-454
(normalisation to Ct average) or miRNA-885-5p (normalisation
to U6) emerged as significant risk predictors (table 3).
DISCUSSION
In a well-defined, population-based cohort including 816 indivi-
duals, we identified differentially expressed miRNAs as predic-
tors for severe knee and hip OA. Applying very stringent
criteria for outcome (arthroplasty) and statistical analyses (stand-
ardisation to U6 as well as Ct average), we discovered let-7e as a
negative, dose-dependent predictor of OA (figure 2). Besides
let-7e, weaker associations emerged for miRNA-454 and
miRNA-885-5p but were not consistently significant after
respective adjustments.
Patients with OA exhibit early signs of cartilage degradation,
synovial inflammation and altered bone structure even before
the disease becomes clinically manifest.4 Conventional radiog-
raphy, which is still considered the gold standard in the diagno-
sis of OA, is insensitive in detecting early disease manifestations.
Magnetic resonance imaging (MRI) is emerging as a more sensi-
tive imaging tool for OA, but is complex and expensive. In add-
ition, MRI may not be sensitive enough to detect very early,
clinically silent periods of OA.32 Thus, stable biochemical
markers that are easily assessed in the peripheral blood or urine
might be ideal measures to diagnose initial stages of OA, predict
and assess disease progression, and monitor effects of disease-
modifying treatments. So far, a large array of biochemical
markers, most of them reflecting bone and cartilage metabolism,
have been studied, but few of them have shown substantial
improvement in predicting OA,23 and none has so far entered
clinical routine. Poor performance and lack of validation in
large clinical trials may have been the major obstacles precluding
their clinical use.
Circulating miRNAs are easily accessible and stable,10 11
which would be convenient for their daily clinical use. The sta-
bility of miRNAs is remarkable since they resist harsh
Table 1 Baseline demographic, lifestyle and laboratory
characteristics in subjects with and without joint replacement
surgery (1995–2010) due to severe osteoarthritis (n=816)
Characteristic*
Joint replacement
1995–2010
p Value†No (n=749) Yes (n=67)
Age, years 62.7±11.3 65.0±9.3 0.053
Male sex, n (%) 380 (50.7) 28 (41.8) 0.161
Body mass index, kg/m2 25.5±3.8 27.0±4.1 0.003
Weight, kg 68.6±12.4 72.0±13.0 0.001
Height, cm 163.7±8.9 163.3±9.6 0.074
Waist circumference, cm 89.9±11.1 93.6±9.8 0.004
Hip circumference, cm 96.6±7.8 100.3±7.7 0.001
Waist-to-hip ratio, cm/cm 0.92±0.07 0.93±0.06 0.369
Social status
Low, n (%) 453 (60.5) 44 (65.7) 0.876
Medium, n (%) 165 (22.0) 12 (17.9)
High, n (%) 131 (17.5) 11 (16.4)
Fasting glucose, mg/dL 102.0±25.0 105.0±19.5 0.944
Smoking, pack-years 13.5±18.1 9.8±14.7 0.194
Total cholesterol, mg/dL 229.2±42.1 231.4±47.9 0.960
HDL cholesterol, mg/dL 58.6±16.3 59.7±15.8 0.199
LDL cholesterol, mg/dL 144.6±37.1 148.9±46.0 0.661
Systolic blood pressure, mm Hg 147.6±20.5 154.0±21.3 0.453
Diastolic blood pressure, mm Hg 86.8±9.2 89.8±8.1 0.236
Uric acid, mg/dL 4.7±1.3 4.8±1.4 0.743
γ-GT, U/L 36.7±41.5 36.1±45.8 0.837
Ferritin, mg/L 134.3±167.4 143.0±162.6 0.571
C-reactive protein, mg/L 1.7 (0.8–3.2) 1.9 (0.9–3.4) 0.479
Prior joint replacement, n (%) 17 (2.3) 1 (1.5) 0.507
*Values presented are unadjusted means±SD, numbers (percentages) or median
(IQR). Factors to convert conventional units into SI units are as follows: glucose
0.05551 and cholesterol 0.02586.
†p Values for the variables age and sex are from unadjusted analyses and those for
body mass index, weight, height, waist circumference, hip circumference and WHR
are age-adjusted and sex-adjusted. All other p values are from general linear models
or logistic regression models adjusted for age, sex and body mass index. For
computation of p values, C-reactive protein was loge-transformed because of a
markedly skewed distribution. Variables in bold were statistically significant.
GT, glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; WHR, waist-to-hip ratio.
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conditions that would normally degrade most RNAs, including
boiling, extreme pH, long-time storage and repeated freeze–
thaw cycles.33 Our data obtained in a large cohort representa-
tive of the general community are the first to raise evidence
that specific miRNAs, such as let-7e, could indeed serve as a
valuable biomarker for OA. Despite the large size of our
cohort, however, the number of joint replacements was com-
paratively low and further studies need to confirm and validate
our findings in other cohorts and ethnicities. Our study was
designed to identify candidate miRNA to predict severe OA;
thus, the validity of let-7e, miRNA-454 and miRNA-885-5p
for early detection and follow-up remains to be addressed.
Table 2 Association between individual microRNAs and joint replacement surgery due to severe osteoarthritis (n=816) follow-up 1995–2010
Fold changes
to control
Unadjusted analysis
Age-adjusted, sex-adjusted and
BMI-adjusted analysis
HR (95% CI) p Value HR (95% CI) p Value
microRNAs
normalised to U6
miRNA-122 1.36 1.17 (0.90 to 1.52) 0.245 1.10 (0.84 to 1.43) 0.499
miRNA-25 0.93 0.91 (0.72 to 1.14) 0.398 0.90 (0.72 to 1.13) 0.375
miRNA-28-3p 0.56 0.83 (0.65 to 1.05) 0.114 0.85 (0.67 to 1.07) 0.166
miRNA-93 0.99 0.98 (0.77 to 1.23) 0.834 0.98 (0.77 to 1.24) 0.833
miRNA-140 0.95 0.96 (0.76 to 1.21) 0.717 0.95 (0.75 to 1.21) 0.668
miRNA-191 0.92 0.86 (0.67 to 1.10) 0.223 0.91 (0.71 to 1.17) 0.465
miRNA-342-3p 0.93 0.87 (0.60 to 1.09) 0.231 0.89 (0.70 to 1.13) 0.333
miRNA-146b 0.96 0.90 (0.71 to 1.15) 0.402 0.92 (0.72 to 1.17) 0.489
miRNA-454 0.85 0.86 (0.67 to 1.09) 0.206 0.77 (0.61 to 0.97) 0.028
miRNA-885-5p 1.12 1.18 (0.91 to 1.54) 0.213 1.24 (0.95 to 1.62) 0.107
miRNA-let-7b 0.87 0.91 (0.72 to 1.15) 0.426 0.93 (0.73 to 1.20) 0.579
miRNA-let-7e 0.66 0.72 (0.57 to 0.92) 0.007 0.75 (0.58 to 0.95) 0.019
microRNAs
normalised to Ct average
miRNA-122 1.63 1.25 (0.95 to 1.64) 0.119 1.15 (0.87 to 1.51) 0.341
miRNA-25 0.89 0.92 (0.74 to 1.15) 0.464 0.91 (0.74 to 1.14) 0.416
miRNA-28-3p 0.91 0.80 (0.63 to 1.01) 0.055 0.83 (0.66 to 1.05) 0.121
miRNA-93 1.08 1.03 (0.81 to 1.32) 0.784 1.03 (0.81 to 1.32) 0.804
miRNA-140 1.08 1.03 (0.81 to 1.31) 0.835 1.01 (0.79 to 1.29) 0.963
miRNA-191 0.95 0.88 (0.69 to 1.11) 0.267 0.97 (0.76 to 1.23) 0.778
miRNA-342-3p 0.88 0.89 (0.71 to 1.13) 0.336 0.91 (0.71 to 1.17) 0.475
miRNA-146b 0.92 1.00 (0.79 to 1.28) 0.974 1.01 (0.80 to 1.29) 0.926
miRNA-454 0.80 0.95 (0.75 to 1.21) 0.686 0.83 (0.65 to 1.04) 0.118
miRNA-885-5p 2.03 1.24 (0.95 to 1.60) 0.110 1.30 (0.99 to 1.70) 0.056
miRNA-let7b 0.87 0.92 (0.73 to 1.17) 0.504 0.97 (0.76 to 1.23) 0.773
miRNA-let-7e 0.45 0.71 (0.56 to 0.90) 0.004 0.76 (0.60 to 0.96) 0.021
Fold changes to control were calculated by dividing the means of loge-transformed miRNA levels in subjects with severe osteoarthritis requiring joint replacement and all other. HRs and
95% CIs were derived from various Cox regression analyses including one miRNA each. The left-hand columns (columns 3 and 4) refer to unadjusted analyses and the right-hand
columns (columns 5 and 6) to analyses adjusted for age, sex and body mass index (BMI). Variables in bold were statistically significant.
Figure 2 Baseline levels of miRNA-let-7e according to the number of surgical joint replacements ( JR) due to severe osteoarthritis. This figure indicates a
dose–response relation. Data are presented separately for miRNA levels normalised to U6 and the Ct average of all miRNAs assessed. Values are
unadjusted geometric means+SE. Numbers of subjects in the groups with no JR, one JR and two or more JR were 732, 66 and 18.
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While our study is the first to investigate the levels of circulat-
ing miRNAs within a large population-based cohort, several
studies have assessed differential miRNA expression in the car-
tilage of OA patients.9 12–17 None of the miRNAs that have
already been associated with physiological or pathological cartil-
age metabolism, however, was differentially expressed in the OA
patients of our cohort. Several reasons might account for these
differences: small study cohorts and differences in the method-
ology of collecting articular cartilage may lead to differences in
miRNA expression profiles. Patient selection and different
cohorts (early vs late disease, mild vs severe disease) might also
contribute to the observed differences. In this context, even the
studies that focused on the miRNA expression in articular cartil-
age reported striking differences in their miRNA profiles. Apart
from that, it is still unclear whether or not the circulating
miRNA signature directly emerges from the articular cartilage
or other tissues. While elegant studies from the cancer field
suggest that differentially expressed miRNAs could indeed
emerge from the pathological tissues,10 34 we have preliminary
data that challenge this concept in OA. In cartilage from patients
receiving hip replacement surgery due to severe OA compared
with patients receiving hip arthroplasty for femoral fracture, we
did not observe a differential expression of our serum miRNA
candidates. In line with our observations, a small study demon-
strated that miRNA expression profiles in the synovial fluid dif-
fered from miRNA signatures in the serum of the matched OA
patients.18 Despite limitations in cohort size and miRNA selec-
tion, these findings suggest that it may well be that miRNA sig-
natures found in OA patients do not stem from the
non-vascularised, bradytrophic cartilage but from other, much
better vascularised tissues, such as the synovia, the bone or the
bone marrow.
Taken together, we identified differentially expressed circulat-
ing miRNAs in patients with severe OA in a large, population-
based cohort. let-7e, and possibly miRNA-454 and
miRNA-885-5p, may represent predictors for severe knee or
hip OA necessitating arthroplasty and could thus be further
developed into predictive biomarkers for OA. let-7e emerged
as the most promising candidate to predict the OA risk since
its association to OA was independent of age, sex and BMI,
and consistent in subgroups and with different standardisation
procedures. Moreover, there was a clear dose–response rela-
tionship (figure 2). Technical innovations, including small dis-
posable microchips to assess OA-specific miRNAs, might foster
the clinical application of this technology. Prior to a potential
clinical use, however, further studies are needed to validate the
candidate miRNAs in different cohorts and for different appli-
cations, such as diagnosis, risk prediction and disease activity,
to assess their incremental value beyond the information pro-
vided by standard risk predictors.
Figure 3 miRNA relevance network inference and analysis. Differential network structure between 12 miRNAs in controls and osteoarthritis cases.
Nodes represent individual miRNAs and edges (links) represent the extent of expression similarity measured using the context likelihood of
relatedness algorithm.
Table 3 Multivariable risk predictors of joint replacement surgery
due to severe osteoarthritis (n=816) follow-up 1995–2010
Variables
Step of
entry
HR (95% CI) per 1 SD
unit increase in variable
levels* p Value
microRNAs
normalised to U6
Age 1.85 (1.39 to 2.45) <0.001
Male sex 0.79 (0.48 to 1.29) 0.340
Body mass index 1.31 (1.04 to 1.64) 0.021
miRNA-let-7e 1 0.70 (0.54 to 0.89) 0.005
miRNA-885-5p 2 1.35 (1.04 to 1.77) 0.025
microRNAs
normalised to Ct average
Age 1.93 (1.45 to 2.57) <0.001
Male sex 0.84 (0.51 to 1.37) 0.472
Body mass index 1.31 (1.05 to 1.65) 0.017
miRNA-let-7e 1 0.70 (0.55 to 0.88) 0.003
miRNA-454 2 0.73 (0.56 to 0.94) 0.017
HRs, 95% CI and p values were derived from multivariable Cox regression analysis.
Variables were selected for inclusion from all miRNAs listed in table 2 using a
forward stepwise selection procedure with a fixed entry of age, sex and body mass
index.
*To facilitate a comparison between the various risk predictors, HRs were calculated
for a 1 SD unit increase in metric variables.
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